Format

Send to

Choose Destination
Am J Kidney Dis. 2014 Apr;63(4):677-90. doi: 10.1053/j.ajkd.2013.11.023. Epub 2014 Jan 7.

Lupus nephritis: the evolving role of novel therapeutics.

Author information

1
Division of Nephrology, Ohio State University Wexner Medical Center, Columbus, OH. Electronic address: rovin.1@osu.edu.
2
Division of Nephrology, Ohio State University Wexner Medical Center, Columbus, OH.

Abstract

Immune complex accumulation in the kidney is the hallmark of lupus nephritis and triggers a series of events that result in kidney inflammation and injury. Cytotoxic agents and corticosteroids are standard of care for lupus nephritis treatment, but are associated with considerable morbidity and suboptimal outcomes. Recently, there has been interest in using novel biologic agents and small molecules to treat lupus nephritis. These therapies can be broadly categorized as anti-inflammatory (laquinamod, anti-tumor necrosis factor-like weak inducer of apotosis, anti-C5, and retinoids), antiautoimmunity (anti-CD20, anti-interferon α, and costimulatory blockers), or both (anti-interleukin 6 and proteasome inhibitors). Recent lupus nephritis clinical trials applied biologics or small molecules of any category to induction treatment, seeking short-term end points of complete renal response. These trials in general have not succeeded. When lupus nephritis comes to clinical attention during the inflammatory stage of the disease, the autoimmune stage leading to kidney inflammation will have been active for some time. The optimal approach for using novel therapies may be to initially target kidney inflammation to preserve renal parenchyma, followed by suppression of autoimmunity. In this review, we discuss novel lupus nephritis therapies and how they fit into a combinatorial treatment strategy based on the pathogenic stage.

KEYWORDS:

Lupus nephritis; biologics; novel therapies; small molecules; systemic lupus erythematosus (SLE)

PMID:
24411715
PMCID:
PMC4159074
DOI:
10.1053/j.ajkd.2013.11.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center